The RGH E-Bulletin this
week highlights some of
the shortcomings of current
osteoporosis therapies and
reports on Romosozumab, a new
humanised monoclonal antibody
that acts against sclerostin, which
has anti-anabolic effects on bone.
Phase II studies have
demonstrated positive primary
endpoints, significantly increasing
bone mineral density (BMD), and
Phase III studies have commenced.
To read the e-bulletin CLICK HERE.The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jan 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jan 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.